Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03298984
Title Ph I Study of Alvocidib and Cytarabine/Duanorubicin (7+3) in Patients With Newly Diagnosed Acute Myeloid Leukemia (AML).
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Tolero Pharmaceuticals, Inc.

acute myeloid leukemia


Alvocidib + Cytarabine + Daunorubicin

Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.